

03 March 2022

Subject: The incidence and treatment of breast cancer

Please find Information as available from RISOH (regional information system for Oncology & Haematology) Nov 21 – Jan 22

PLEASE NOTE: Aromatase Inhibitors are not prescribed via RISOH, but prescribed by GP so information not available in the RISOH Query field.

Question 1:

How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies?

- (blank = 0 patients)

For therapies below with the named AI's included in the query, figure is for the therapy prescribed via RISOH

- Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent :
 - **Prescribed by GP therefore not available at the Trust**
- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
 - = <5
- Abemaciclib + Fulvestrant
 - = <5
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
 - = <5
- Atezolizumab + Nab-paclitaxel/Paclitaxel
 - = <5
- Capecitabine as a single agent
 - = 25
- Carboplatin or Cisplatin as a single agent
 - = <5
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fulvestrant as a single agent
 - = 16
- Lapatinib
- Neratinib
- Parp Inhibitors (Olaparib/Talazoparib)
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
 - = 45
- Palbociclib + Fulvestrant
 - = 5
- Pembrolizumab
- Pertuzumab + Trastuzumab + Docetaxel

03 March 2022

- = 5
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
 - = 8
- Ribociclib + Fulvestrant
 - = <5
- Sacituzumab Govitecan
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
 - = 19
- Trastuzumab as a single agent or in combination
 - = 12
- Trastuzumab emtansine
 - = 9
- Transtuzumab deruxtecan
- Vinorelbine as a single agent
 - = <5
- Any other active systemic anti-cancer therapy :
 - Goserelin = <5
 - Gemcitabine /Carboplatin = <5
 - Docetaxel/Cyclophosphamide = <5
 - D-Phesgo = <5
 - EC-D & Trast = <5
 - EC- D = 17
 - ECD Phesgo = 11
 - EC-Pac/Carbo = 10
 - ECPPhesgo = <5
 - EC-Wkly Pac = <5
 - FEC 100 = <5
 - FEC WklyP Her = <5
 - FEC-50 = 7
 - FEC- 60 = <5
 - FEC-D = <5
 - FEC-D & Trast =5
 - FECDPhesgo = 12
 - FECDT18P3 = <5
 - FEC Weekly Paclitaxel = <5
 - FECWyPacT18P18 = <5

Question 2:

In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, letrozole) as a single agent?

- Prescribed by GP therefore not available at the Trust